TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00646438

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Strict Glycemic Control for one year post-op CABG
Description: The CDE and Study Coordinator will also meet with the patient in the hospital to show how the Lifescan One-Touch Ultra II glucometer works and review the study follow-up schedule. Patients will be sent home with the Lifescan One-Touch Ultra II glucometer and a supply of strips.~Post-Discharge Period Patients will meet alternatively with the CDE and study doctor on a specific schedule including every week for the first month, every 2 weeks in the second month, and every month thereafter till the 12th month. During these sessions the BG records will be downloaded from the Lifescan One-Touch Ultra II glucometer and reviewed to see patterns and any areas that could be improved or changed.~For all patients in the study arm, the medications that are being taken and the results of glucose monitoring charts will be reviewed weekly with endocrinologists so that any additional recommendations may be made to improve glucose control.
Study: NCT02257125

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high incentive
Description: Subjects are required to use their arms in order to control a virtual arm on a computer screen to prevent meteors from destroying a planet. The game includes visual effects and monetary rewards.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: low incentive
Description: Subjects are required to use their arms in order to control a virtual hand on a computer screen to prevent objects from reaching the bottom. The game does not include visual effects or monetary rewards.
Study: NCT03520205

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus Lumborum Block
Description: Bilateral block using ultrasound will be performed before surgery and after surgery on patient using Stimuplex 100mm needle with Bupivacaine 0.25% 0.4 mL/kg, maximum dose 25 mL each side under general anaesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Epidural
Description: Patient will be given 6 mL/hour of Bupivacaine 0.25% for intraoperative analgesia and continued epidural 6 mL/hour Bupivacaine 0,125% as postoperative analgesia in 24 hours.
Study: NCT01428440

Intervention type: RADIATION
Group type: OTHER
Intervention: 18FML10
Description: apoptosis imaging radio ligand
Study: NCT02372110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPA, ANS stimulation
Description: Oral administration of Hydrocortisone will increase HPA axis activity. Oral administration of Caffeine will boost ANS activity

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two cellulose placebo capsules filled with acidophilus powder will be administered to subjects who are randomly assigned to the placebo condition
Study: NCT01894867

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: magnesium
Description: supply magnesium oxide for 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04351386

Intervention type: DEVICE
Intervention: AF Detection
Description: Recording PPG and single-lead ECG signals with the Withings HWA09 and ECG signal for the reference 12-lead ECG

Intervention type: DEVICE
Intervention: AF Detection
Description: Recording PPG and single-lead ECG signals with the Withings HWA09 and ECG signal for the reference 12-lead ECG

Intervention type: DEVICE
Intervention: AF Detection
Description: Recording PPG and single-lead ECG signals with the Withings HWA09 and ECG signal for the reference 12-lead ECG
Study: NCT00714506

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet and physical activity
Description: lifestyle weight reduction - low fat eating, low calorie and physical activity

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity control
Description: physical activity plus successful aging health education
Study: NCT02655952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foxy-5
Study: NCT05096975

Intervention type: OTHER
Intervention: Evaluation of the CBCL-A-A-A and HiPIC in children with ADHD and with ED or without ED
Description: The intervention involves the completion of two questionnaires by parents at child psychiatry unit of Montpellier University Hospital when children come to participate in a psychometric assessment or when parents or children participate in therapeutic group.~All parents completed Child Behavior Checklist (CBCL; Achenbach \& Rescorla, 2001), a 118-item questionnaire to measure emotional and behavior problems in 4 to 18-years-old children in the past six months and Hierarchical Personality Inventory for Children (HiPIC, Mervielde \& De Fruyt, 1999, a 144-item questionnaire to obtain a profile of the personality of 6 to 12-year-old children.
Study: NCT00550394

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: quetiapine and placebo
Description: Dosing Schedule and Titration of Quetiapine: open-label quetiapine beginning day 1 at 100 mg/day titrated to 400 mg/day by the end of week 1~Dosing Schedule and Titration of Topiramate:~All subjects will be randomized to topiramate or matching placebo which will be administered in a double-blind manner.~Topiramate/Placebo titrated from 25 mg twice daily to 150 mg bid by week 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine and Topiramate
Description: Dosing Schedule and Titration of Quetiapine:~open-label quetiapine beginning day 1 at 100 mg/day titrated to 400 mg/day by the end of week 1~Dosing Schedule and Titration of Topiramate:~All subjects will be randomized to topiramate or matching placebo which will be administered in a double-blind manner.~Topiramate/Placebo titrated from 25 mg twice daily to 150 mg bid by week 4.
Study: NCT05096975

Intervention type: OTHER
Intervention: Evaluation of the CBCL-A-A-A and HiPIC in children with ADHD and with ED or without ED
Description: The intervention involves the completion of two questionnaires by parents at child psychiatry unit of Montpellier University Hospital when children come to participate in a psychometric assessment or when parents or children participate in therapeutic group.~All parents completed Child Behavior Checklist (CBCL; Achenbach \& Rescorla, 2001), a 118-item questionnaire to measure emotional and behavior problems in 4 to 18-years-old children in the past six months and Hierarchical Personality Inventory for Children (HiPIC, Mervielde \& De Fruyt, 1999, a 144-item questionnaire to obtain a profile of the personality of 6 to 12-year-old children.

Intervention type: OTHER
Intervention: Evaluation of the CBCL-A-A-A and HiPIC in children with ADHD and with ED or without ED
Description: The intervention involves the completion of two questionnaires by parents at child psychiatry unit of Montpellier University Hospital when children come to participate in a psychometric assessment or when parents or children participate in therapeutic group.~All parents completed Child Behavior Checklist (CBCL; Achenbach \& Rescorla, 2001), a 118-item questionnaire to measure emotional and behavior problems in 4 to 18-years-old children in the past six months and Hierarchical Personality Inventory for Children (HiPIC, Mervielde \& De Fruyt, 1999, a 144-item questionnaire to obtain a profile of the personality of 6 to 12-year-old children.
Study: NCT03758209

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERAS
Description: Enhanced Recovery Program, including preoperative 4 weeks nutritional supplementation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS
Description: Enhanced Recovery Program, including preoperative 4 weeks nutritional supplementation.
Study: NCT01600638

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Zeltiq System
Description: Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
Study: NCT03557099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hetrombopag Olamine
Description: once daily
Study: NCT04297150

Intervention type: DRUG
Intervention: Apixaban
Description: Drug indicated for the treatment of NVAF

Intervention type: DRUG
Intervention: Edoxaban
Description: Drug indicated for the treatment of NVAF

Intervention type: DRUG
Intervention: Rivaroxaban
Description: Drug indicated for the treatment of NVAF

Intervention type: DRUG
Intervention: Dabigatran
Description: Drug indicated for the treatment of NVAF
Study: NCT02711592

Intervention type: GENETIC
Group type: OTHER
Intervention: Genetic Panel for Analgesics
Description: All patients will receive genetic test panel to determine individualized optimal pain management following Total Knee Arthroplasty.
Study: NCT00858130

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VeinOPlus
Description: The Veinoplus® device electrically stimulates leg muscles via motor nerves, causing calf muscle contractions. The two electrodes are placed on the central part of the calf muscle on the back of the legs, and once the device is turned on, the length of treatment is 20 minutes. The device has a variable intensity setting which allows subjects to choose their own level and change the stimulations mid-cycle if desired. Subjects will use the device however they see fit for 2 months.
Study: NCT01372462

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIOV - Room Air
Description: Noninvasive ventilation with device powered by compressed room air.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIOV - Oxygen
Description: Noninvasive ventilation with device powered by compressed medical (100%) oxygen.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Cannula Oxygen
Description: Supplemental oxygen delivered using a standard nasal cannula connected to 100% medical oxygen.
Study: NCT01793896

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control period
Description: Analysis at recruitment and after a month without any intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet Group
Description: selected subjects will adopt a Mediterranean low-AGE diet. We will not include red wine in the Mediterranean diet (7 Kilocalories (KCal)/g), in order to attain more weight loss. Each subject will be instructed to reduce 500 Kcal of their estimated total daily energy requirements, so theoretically they will be able to reduce 5 - 10 % of their body weight in 3 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise group
Description: The intervention will consist of 3 weekly 1 hour sessions (5 minutes of preconditioning, followed by 20 minutes cycling, brisk walking or jogging at 65-70 % maximal aerobic capacity, then 25 minutes resistance weight-lifting exercises and finally 10 minutes of stretching). Exercise intensity will be increased weekly according to the Borg Scale intensity. The exercise intervention will be supervised by physical education teachers, registering attendance at every session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet + Exercise
Description: these patients will be incorporated to receive both Mediterranean diet plus exercise interventions
Study: NCT03338998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAF312 solution
Description: Solution for intravenous (IV) infusion - 4.5mg/4.5mL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo for BAF312 solution
Description: Solution for intravenous (IV) infusion - 0mg/4.5mL matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAF312 tablet
Description: 2 mg film-coated tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo for BAF312 tablet
Description: 0 mg film-coated tablet matching placebo
Study: NCT02502578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNT-01 500 mg capsule
Description: After being informed about the study and potential risks, all patients giving written informed consent undergo screening tests to determine eligibility for study enrollment. On Day 1, patients who meet the eligibility criteria will start taking CNT-01 500mg orally three times daily for 14 days. On Day 15, patients will take CNT-01 500 mg only once after blood drawing.
Study: NCT05728905

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Description: Intervention with therapeutic exercise: coordination, relaxation and disc recapture exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Description: Intervention with therapeutic exercise: coordination, relaxation and disc recapture exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orthopedic manual therapy
Description: Intervention with orthopedic manual therapy: traction, ventral sliding and massage.
Study: NCT03648983

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: arm circumference measurement
Description: Undergo arm circumference measurement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: arm circumference measurement
Description: Undergo arm circumference measurement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioimpedance spectroscopy
Description: bioimpedance spectroscopy
Study: NCT00534391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neomycin sulfate, polymyxin B sulfate and gramicidin
Description: to the effected eye 4 times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Artificial tear
Description: 4 times daily
Study: NCT02955108

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Distractive Auditory Stimuli
Description: Participants will self-select 1 music piece from a list of choices to keep the rhythm and tempo consistent throughout the 6MWT. The instructions to participants for selecting the music will be standardized. TThe music volume will be standardized to be moderately loud as rated by participants for the music condition. Participants will not be specifically instructed to synchronize their walking movements with the music tempo. The music is based on a cognitive therapy (distraction) strategy conceptual framework. Music will be played during the 6MWT (in-task) only.
Study: NCT00519831

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: 400 mg/m² week 1,then 250 mg/m² weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinflunine
Description: Vinflunine 320 mg/m² every 21 days
Study: NCT03359317

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: jogging
Description: Jogging as instructed for 1 year
Study: NCT02165969

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic endonasal surgery with UPSIT
Study: NCT03886805

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual task with variable- and fixed-priority instructions
Description: The participants were asked to perform dual-task activities focused, interchangeable or simultaneously, on balance (motor tasks) and on cognitive tasks performance, according to the instructional priority established by the physical therapist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dual-task with variable-priority instructions
Description: The participants were asked to spend half the session focused on balance (motor tasks) and half the session focused on cognitive tasks performance, according to the instructional priority established by the physical therapist.
Study: NCT03572764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351
Description: -CPX-351 will be provided by Jazz Pharmaceuticals

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Research skin biopsy
Description: -And/or buccal swab~* Pre-treatment~* Post-induction (no earlier than Day 28 and no later than Day 56 from last induction)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Research blood draw
Description: * Pre-treatment~* Post-induction (no earlier than Day 28 and no later than Day 56 from last induction)~* Post-consolidation 1 (if applicable)~* Post-consolidation 2 (if applicable)~* Post-transplant Day 30 (if applicable)~* Post-transplant Day 100 (if applicable)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Research bone marrow aspirate
Description: * Pre-treatment~* Post-induction (no earlier than Day 28 and no later than Day 56 from last induction)~* Post-consolidation 1 (if applicable)~* Post-consolidation 2 (if applicable)~* Post-transplant Day 30 (if applicable)~* Post-transplant Day 100 (if applicable)
Study: NCT03303365

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: stereotactic radiosurgery (SRS)
Description: All patients will receive a pre-treatment cranial MRI for diagnostic and treatment planning purposes.~In Arm A, the contrast-based T1-weighted SPACE sequence is utilized for GTV definition. In Arm B, the contrast-based T1-weighted three-dimensional MPRAGE sequence is utilized for GTV definition. In both cases the GTV consists of all contrasted tissue associated with the target lesion and all additional tissue judged by an experienced physician to be part of the suspect target lesion. To the GTV a PTV margin of 1 mm is added by isotropic expansion that can be slightly modified if deemed necessary by the treating physician (e.g. intersection with adjoining OAR).~Dose prescription to the PTV for target lesions will be as follows:~* 20 Gy to the 70%-isodose (lesions \< 2 cm max. diameter)~* 18 Gy to the 70%-isodose (lesions 2 - 3 cm max. diameter)~* 6 x 5 Gy to the conformally surrounding isodose (lesions \> 3 cm max. diameter)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiosurgery (SRS)
Description: All patients will receive a pre-treatment cranial MRI for diagnostic and treatment planning purposes.~In Arm A, the contrast-based T1-weighted SPACE sequence is utilized for GTV definition. In Arm B, the contrast-based T1-weighted three-dimensional MPRAGE sequence is utilized for GTV definition. In both cases the GTV consists of all contrasted tissue associated with the target lesion and all additional tissue judged by an experienced physician to be part of the suspect target lesion. To the GTV a PTV margin of 1 mm is added by isotropic expansion that can be slightly modified if deemed necessary by the treating physician (e.g. intersection with adjoining OAR).~Dose prescription to the PTV for target lesions will be as follows:~* 20 Gy to the 70%-isodose (lesions \< 2 cm max. diameter)~* 18 Gy to the 70%-isodose (lesions 2 - 3 cm max. diameter)~* 6 x 5 Gy to the conformally surrounding isodose (lesions \> 3 cm max. diameter)
Study: NCT02460627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine adhesive tape
Description: 700 mg for 12 hours

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Adhesive tape
Description: For 12 hours
Study: NCT02368626

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndyMed Pro™ RF Micro-Needles
Description: RF Micro-needles ablation treatments
Study: NCT03716336

Intervention type: OTHER
Group type: OTHER
Intervention: Resistance exercise
Description: Resistance exercise were performed for all participants in group (A) only included 9 exercise for big muscles of upper limbs (shoulder flexors muscles, shoulder extensors and shoulder abductors), lower limbs (hip flexors, hip extensors and knee flexors and knee extensors) and abdominal muscle using moderate work load (60 - 75% of IRM) 1set of 10 repetitions, progressing to 2 sets of 10 repetitions after four weeks for 20 minutes
Study: NCT04556448

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aligners
Description: Clear aligners

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clear braces
Description: Clear braces
Study: NCT04177875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teripalimab
Description: Teripalimab Injection 240mg/6ml fixed dose (3mg/kg for patients weighing less than 40kg) ,injection on day 1, each infusion for 30min (no less than 60 minutes for the first injection); every 3 weeks. docetaxel dose was 75mg/m2, injection on day 1;Albumin-bound Paclitaxel (no anti-allergic treatment required), 260mg/m2, injection on day 1; Cisplatin was 75mg/m2, injected on day 1.A total of two treatment cycles.
Study: NCT03555071

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine manufactured at commercialized scale
Description: Single subcutaneous injection of the investigated live attenuated varicella vaccine (0.5 ml) on Day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine manufactured at commercialized scale
Description: Single subcutaneous injection of the investigated live attenuated varicella vaccine (0.5 ml) on Day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine manufactured at commercialized scale
Description: Single subcutaneous injection of the investigated live attenuated varicella vaccine (0.5 ml) on Day 0

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccine manufactured at trial-scale
Description: Single subcutaneous injection of the control live attenuated varicella vaccine (0.5 ml) on Day 0
Study: NCT00552994

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cypher Select plus
Description: Drug eluting stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience V stent
Description: Drug eluting stent
Study: NCT01947894

Intervention type: OTHER
Intervention: Non Interventional Study
Description: Non Interventional Study
Study: NCT00204412

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flax lignan
Description: 543 mg SDG per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Flax lignan
Description: 543 mg SDG per day

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise (walking)
Description: walking 45 minutes per day 5 days per week
Study: NCT00719537

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: Aspirin 81 mg once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 81 mg once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo 1 tab Daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: Oral Progesterone 200 mg Twice Daily
Study: NCT05242263

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Control Training (ACT) with ABV feedback
Description: At the beginning of each session, participants will complete 45 standard dot-probe trials as described above. Participants' ABV on these trials will be calculated and set as their personal baseline (see below for ABV calculation). In the following 165-training trials, participants will receive feedback: when their online-calculated ABV will be below their baseline screen background will be green whereas its color will be red when their online ABV score will be higher than their baseline. Patients will be instructed to try to keep the background green for as long as possible.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Attention Control Training (ACT) with yoked sham feedback
Description: Participants in this group will be exposed to the same task as in the active group but will receive sham feedback that is unrelated to their ABV during task performance. They will be presented with a feedback that is yoked to the one given to a participant in the training group.